Hodgkin's Lymphoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 -- GlobalData

June 30, 2011 - PRLog -- GlobalData estimates that the HL therapeutics market grew at a Compound Annual Growth Rate (CAGR)
of 4.3% from $270.6m in 2005 to $333.3m in 2010. The market is expected to increase at a CAGR of 6.8% over the next seven years to reach $527.2m by 2017. This growth is primarily attributed to the
anticipated launch of new therapies such as brentuximab vedotin (SGN-35) and panobinostat (LBH-589)
during the forecast period, drugs which are expected to change the treatment paradigm of HL.

GlobalData’s research indicates that the HL therapeutics market is attractive, with high unmet need in
terms of safety. The unmet need in the market is currently around 55%, equal to a value of approximately $183.3m. The existing chemotherapy regimens available in the market are efficacious; however the incidence of associated adverse effects is very high. Any novel pipeline product which can offer an improved safety profile along with high efficacy is therefore expected to gain market acceptance

GlobalData’s analysis demonstrates that the HL therapeutics pipeline is strong, with 23 molecules in various phases of clinical development. The US Food and Drug Administration (FDA) have accepted a
Biologics License Application (BLA) for brentuximab vedotin, which is intended for the treatment of
patients with relapsed or refractory HL. Brentuximab vedotin was granted a six-month priority review
designation and received orphan drug status in the US and Europe. The drug is expected to be launched
in the market in 2012. Furthermore, in Phase III of clinical development two molecules, panobinostat and Rituxan (rituximab)-supplemented ABVD (doxorubicin+bleomycin+vinblastine+dacarbazine), are expected to be launched in the market soon. Panobinostat received orphan drug designation in the US and Europe for the treatment of HL and is expected to launch in 2014. There are 14 molecules in Phase II clinical trials and six molecules in Phase I clinical trials, making the pipeline for the HL therapeutics market strong. If approved and launched, these products are expected to uncover new treatment options for HL patients, offering improved safety and efficacy profiles in comparison with the existing drugs in the market.

For Sample Pages, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData, the industry analysis specialist, has released its new report, “Hodgkin's Lymphoma
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global Hodgkin’s Lymphoma Therapeutics market. The report identifies the key trends shaping and driving the global Hodgkin’s Lymphoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global Hodgkin’s Lymphoma Therapeutics
sector. This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Hodg...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe:       +44 207 753 4299
      +44 1204 543 533
Asia Pacific:    +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

End